Top

Published in:

01-04-2014 | Research

Down-Regulation of BAX Gene During Carcinogenesis and Acquisition of Resistance to 5-FU in Colorectal Cancer

Authors: Mehdi Manoochehri, Ashraf Karbasi, Mojgan Bandehpour, Bahram Kazemi

Published in: Pathology & Oncology Research | Issue 2/2014

Abstract

Carcinogenesis and resistance to chemotherapy could be as results of expression variations in apoptosis regulating genes. Changes in the expression of apoptosis interfering genes may contribute to colorectal carcinogenesis and resistance to 5-Flourouracil (5-FU) during treatment schedule period. The present study aimed to evaluate the expression of pro-apoptotic and anti-apoptotic genes in colorectal cancer tumor tissues, normal adjacent tissues, and tumor colorectal cancer cell line during acquiring resistance to 5-FU in HT-29 based on Bolus treatment protocol. The normal and tumor tissues were obtained from hospital after surgery and total RNA was extracted for expression analysis. The HT-29 colorectal cancer cell line was cultured and exposed with 5-FU in three stages based on Bolus protocol. The MTT assay and Real Time PCR were carried out to determine the sensitivity to the drug and expression of desired genes, respectively. The obtained data showed that Proapoptotic genes, BAX and BID, were down-regulated in resistant derivate cells compared to wild type HT-29 cells. On the other hand Antiapoptotic genes, CIAP1 and XIAP, showed upregulation in resistant cells compared to wild type ones. Furthermore, BAX and FAS genes showed down-regulation in tumor samples in comparison to normal adjacent tissues. In conclusion, the results of our study suggest that BAX down-regulation could contribute as an important factor during both colorectal carcinogenesis and cell resistance to 5-FU.

Herszényi L, Tulassay Z (2010) Epidemiology of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci 14(4):249–258PubMed

Naishadham D, Lansdorp-Vogelaar I, Siegel R, Cokkinides V, Jemal A (2011) State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol Biomarkers Prev 20(7):1296–1302PubMedCrossRef

Pourhoseingholi MA (2012) Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol 4(4):68–70PubMedCentralPubMedCrossRef

Park S, Bae J, Nam BH, Yoo KY (2008) Aetiology of cancer in Asia. Asian Pac J Cancer Prev 9(3):371–380PubMed

Koehler A, Bataille F, Schmid C, Ruemmele P, Waldeck A, Blaszyk H, Hartmann A, Hofstaedter F, Dietmaier W (2004) Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol 204(1):65–74PubMedCrossRef

Fukushima T, Takenoshita S (2001) Colorectal carcinogenesis. Fukushima J Med Sci 47(1):1–11PubMedCrossRef

Watson AJ (2004) Apoptosis and colorectal cancer. Gut 53(11):1701–1709PubMedCentralPubMedCrossRef

Shaib W, Lee V, Saif MW (2009) Bolus 5-fluorouracil as an alternative modality to infusion 5-fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity. In Vivo 23(5):821–826PubMed

Berger FG, Berger SH (2006) Thymidylate synthase as a chemotherapeutic drug target: where are we after fifty years? Cancer Biol Ther 5(9):1238–1241PubMedCrossRef

10.

Buroker TR, O’Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Kardinal CG, Gesme DH Jr (1994) Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12(1):14–20PubMed

11.

Piedbois P, Rougier P, Buyse M, Pignon JP, Ryan L, Hansen R, Zee B, Weinerman B, Pater J, Leichman C, Macdonald J, Benedetti J, Lokich J, Fryer J, Brufman G, Isacson R, Laplanche A, Levy E (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 16(1):301–308

12.

Schmidt WM, Kalipciyan M, Dornstauder E, Rizovski B, Steger GG, Sedivy R, Mueller MW, Mader RM (2004) Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer 112(2):200–212PubMedCrossRef

13.

Zhang N, Yin Y, Xu SJ, Chen WS (2008) 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13(8):1551–1569PubMedCrossRef

14.

Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587(2–3):194–205PubMedCrossRef

15.

Grem JL (2005) Screening for dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 11(14):5067–5068PubMedCrossRef

16.

Arnold CN, Goel A, Boland CR (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106(1):66–73PubMedCrossRef

17.

Akao Y, Noguchi S, Iio A, Kojima K, Takagi T, Naoe T (2011) Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells. Cancer Lett 300(2):197–204PubMedCrossRef

18.

Choi S, Ku JL (2011) Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression. Biochem Biophys Res Commun 412(2):207–213PubMedCrossRef

19.

Humeniuk R, Menon LG, Mishra PJ, Gorlick R, Sowers R, Rode W, Pizzorno G, Cheng YC, Kemeny N, Bertino JR, Banerjee D (2009) Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther 8(5):1037–1044PubMedCrossRef

20.

Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T (2002) Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98(4):498–504PubMedCrossRef

21.

Shi X, Liu S, Kleeff J, Friess H, Büchler MW (2002) Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62(4):354–362PubMedCrossRef

22.

Meng J, Zhang HH, Zhou CX, Li C, Zhang F, Mei QB (2012) The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways. Oncol Rep 28(1):384–388PubMed

23.

Pizzorno G, Handschumacher RE (1995) Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem Pharmacol 49(4):559–565PubMedCrossRef

24.

Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2(4):277–288PubMedCrossRef

25.

Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94(4):481–490PubMedCrossRef

26.

Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495–516PubMedCentralPubMedCrossRef

27.

Kaufmann T, Strasser A, Jost PJ (2012) Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 19(1):42–50PubMedCentralPubMedCrossRef

28.

Stevenson L, Allen WL, Proutski I, Stewart G, Johnston L, McCloskey K, Wilson PM, Longley DB, Johnston PG (2011) Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway. PLoS One 6(5):e20276PubMedCentralPubMedCrossRef

29.

Samuel S, Fan F, Dang LH, Xia L, Gaur P, Ellis LM (2011) Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 30(10):1205–1212PubMedCentralPubMedCrossRef

30.

Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS (2002) BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4(11):842–849PubMedCrossRef

31.

Miao J, Chen GG, Chun SY, Chak EC, Lai PB (2004) Bid sensitizes apoptosis induced by chemotherapeutic drugs in hepatocellular carcinoma. Int J Oncol 25(3):651–659PubMed

32.

Li Y, Jian Z, Xia K, Li X, Lv X, Pei H, Chen Z, Li J (2006) XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 32(3):288–296PubMedCrossRef

33.

Nomura T, Yamasaki M, Nomura Y, Mimata H (2005) Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 14(4):993–997PubMed

34.

Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, Okabe M, Ando T, Murata Y, Sasaki H, Takami K, Yamamura A, Shibata C, Sasaki I (2009) Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 100(5):903–913PubMedCrossRef

35.

Katkoori VR, Suarez-Cuervo C, Shanmugam C, Jhala NC, Callens T, Messiaen L, Posey J 3rd, Bumpers HL, Meleth S, Grizzle WE, Manne U (2010) Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol 1(2):76–89PubMedCentralPubMed

36.

Guillen-Ahlers H, Suckow MA, Castellino FJ, Ploplis VA (2010) Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden. PLoS One 5(2):e9070PubMedCentralPubMedCrossRef

37.

Butler LM, Dobrovic A, Bianco T, Cowled PA (2000) Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma. Br J Cancer 82(1):131–135PubMedCentralPubMedCrossRef

38.

Petak I, Danam RP, Tillman DM, Vernes R, Howell SR, Berczi L, Kopper L, Brent TP, Houghton JA (2003) Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 10(2):211–217PubMedCrossRef

39.

Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B (2000) Role of BAX in the apoptotic response to anticancer agents. Science 290(5493):989–992PubMedCrossRef

40.

Jansson A, Sun XF (2002) Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol 20(3):811–816PubMedCrossRef

Title: Down-Regulation of BAX Gene During Carcinogenesis and Acquisition of Resistance to 5-FU in Colorectal Cancer
Authors: Mehdi Manoochehri
Ashraf Karbasi
Mojgan Bandehpour
Bahram Kazemi
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 2/2014
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-013-9695-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Ephrin Receptor (Eph) -A1, -A2, -A4 and -A7 Expression in Mobile Tongue Squamous Cell Carcinoma: Associations with Clinicopathological Parameters and Patients Survival

MicroRNA-21 Promotes Oral Cancer Invasion via the Wnt/β-Catenin Pathway by Targeting DKK2

Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer—A Phase I-II Study

Expressions of CD147, MMP-2 and MMP-9 in Laryngeal Carcinoma and its Correlation with Poor Prognosis

Functional Modules Analysis Based on Coexpression Network in Pancreatic Ductal Adenocarcinoma

Decreased expression of microRNA-206 correlates with poor clinical outcome in patients with malignant astrocytomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer